# A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

> **NCT05418101** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** VIS171
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05418101
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-03-13
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05418101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05418101, "A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05418101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*